Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIKE-1 (Tamibarotene) with Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
NCT05064618Phase 2Recruiting
- Sponsor
- Nagoya University
- Start
- Aug 2021
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tamibarotene in pancreatic cancer (PC), sponsored by Nagoya University. Started Aug 2021; status: recruiting.
02
Drugs
tamibarotene
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05064618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064618.